ChromaDex eyes mainstream commercialisation as NIAGEN gets FDA nod


Date:

(MENAFN- ProactiveInvestors)Chromadex (OTCMKTS:CDXC) a developer of wellness and dietary products has been boosted by a clearance from the US Food and Drugs Administration (FDA). The company's NIAGEN product has received new dietary ingredient (NDI) status from the FDA. NIAGEN is a referred to as a 'nicotinamide riboside'. The company says the ingredient can elevate an enzyme in the blood which in turn can support mitochondrial performance and energy - in other words it can keep cells healthier for longer. A decrease in mitochondrial health can lead to age-related health issues it said. Chromadex has patent protection for NIAGEN and it now following FDA clearance it expects to move forward with mainstream commercialisation of the product. Frank Jaksch Chromadex chief executive in a statement said: Achieving NDI status is a significant milestone given that the FDA objected approximately 88% of NDI notifications in FY 2014. 'NDI status opens the door for the mainstream commercialization of NIAGEN® in dietary supplements.'

ProactiveInvestors - N.America

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.



More Story

Search